Jazz Pharmaceuticals PLC (JAZZ)

NASDAQ: JAZZ · IEX Real-Time Price · USD
157.60
-1.12 (-0.71%)
Aug 17, 2022 4:00 PM EDT - Market closed
-0.71%
Market Cap 9.88B
Revenue (ttm) 3.48B
Net Income (ttm) -51.87M
Shares Out 62.68M
EPS (ttm) -7.37
PE Ratio n/a
Forward PE 8.88
Dividend n/a
Ex-Dividend Date n/a
Volume 577,192
Open 157.89
Previous Close 158.72
Day's Range 157.52 - 159.31
52-Week Range 117.64 - 169.98
Beta 0.69
Analysts Buy
Price Target 205.93 (+30.7%)
Earnings Date Aug 3, 2022

About JAZZ

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in nar... [Read more...]

Industry Pharmaceuticals
IPO Date Jun 1, 2007
Employees 3,200
Stock Exchange NASDAQ
Ticker Symbol JAZZ
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 24 analysts, the average rating for JAZZ stock is "Buy." The 12-month stock price forecast is 205.93, which is an increase of 30.67% from the latest price.

Price Target
$205.93
(30.67% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Wall Street Analysts Predict a 25% Upside in Jazz (JAZZ): Here's What You Should Know

The mean of analysts' price targets for Jazz (JAZZ) points to a 25.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in r...

JAZZ or CORT: Which Is the Better Value Stock Right Now?

JAZZ vs. CORT: Which Stock Is the Better Value Option?

Other symbols: CORT

Jazz's (JAZZ) Q2 Earnings Beat, New Drugs Post Robust Sales

JAZZ's Q2 earnings and sales beat expectations on strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals. The company affirms its 2022 guidance.

Jazz Pharmaceuticals (JAZZ) Q2 Earnings and Revenues Beat Estimates

Jazz (JAZZ) delivered earnings and revenue surprises of 2.38% and 2.71%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance

DUBLIN , Aug. 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2022, affirmed 2022 financial guidance1 and provided business up...

2 Growth Stocks That Are Unapologetically Crushing the Bear Market

There's more than one factor driving recent outperformance of these shares.

Other symbols: IONS

Does Jazz (JAZZ) Have the Potential to Rally 25% as Wall Street Analysts Expect?

The mean of analysts' price targets for Jazz (JAZZ) points to a 25.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in r...

Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

JAZZ vs. STVN: Which Stock Is the Better Value Option?

JAZZ vs. STVN: Which Stock Is the Better Value Option?

Other symbols: STVN

Jazz Pharmaceuticals to Report 2022 Second Quarter Financial Results on August 3, 2022

DUBLIN , July 20, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 second quarter financial results on Wednesday, August 3, 2022, after the close...

3 Reasons Why Jazz (JAZZ) Is a Great Growth Stock

Jazz (JAZZ) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Best Momentum Stocks to Buy for July 13th

JAZZ, GKOS and SPPI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13, 2022.

Other symbols: GKOSSPPI

3 Drugmaker Stocks Worth Buying to Boost Your Portfolio Health

Merck (MRK), Bayer (BAYRY) and Jazz Pharmaceuticals (JAZZ) are three large drugmakers that are good stocks to buy.

Other symbols: MRK

Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

How Much Upside is Left in Jazz (JAZZ)? Wall Street Analysts Think 28%

The average of price targets set by Wall Street analysts indicates a potential upside of 28.5% in Jazz (JAZZ). While the effectiveness of this highly sought-after metric is questionable, the positive tr...

This Exciting Growth Sector Is Predicted to Keep Doubling Until 2028

The cannabis pharmaceuticals market is still in its infancy.

Other symbols: PFE

JAZZ vs. STVN: Which Stock Should Value Investors Buy Now?

JAZZ vs. STVN: Which Stock Is the Better Value Option?

Other symbols: STVN

What Bear Market? These 2 Stocks Are Killing It.

What else do these companies have in store?

Other symbols: LLY

Two-Minute Drill: JAZZ, BIIB & BABA

Jessica Inskip, OptionsPlay director, joins ‘Closing Bell: Overtime' to give her favorite stock picks in this market, including Jazz Pharma, Biogen and Alibaba.

Other symbols: BABABIIB

JAZZ's Late-Stage Multiple Sclerosis Study on Nabiximols Fails

JAZZ's phase III study evaluating nabiximols oromucosal spray for clinical measures of spasticity in multiple sclerosis patients fails to meet the primary endpoint.

Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Pa...

Nabiximols oromucosal spray continues to be evaluated in ongoing clinical trials in multiple sclerosis spasticity DUBLIN , June 28, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today ann...

Stock Market Plunge: 5 Unstoppable Stocks Begging to Be Bought

Opportunistic investors can snag some amazing deals with the Nasdaq and S&P 500 in a bear market.

Other symbols: DISIIPRISRGNOV

3 Stocks That Could Double by 2025

These companies have realistic prospects of achieving tremendous growth.

Other symbols: AXSMTWST

2 Cheap Stocks to Buy Right Now

These stocks are outperforming the market this year.

Other symbols: BMY

3 Marijuana Stocks That May See A Turnaround In Trading This Month

Top Marijuana Stocks To Watch For More Momentum In June The post 3 Marijuana Stocks That May See A Turnaround In Trading This Month appeared first on Marijuana Stocks | Cannabis Investments and News. Ro...

Other symbols: ABBVSMG